09:17 AM EST, 12/23/2024 (MT Newswires) -- VYNE Therapeutics ( VYNE ) shares were edging higher Monday morning after the biopharmaceutical company reported "positive" phase 1a results for its novel BD2-selective BET inhibitor VYN202.

The company said the results support the inhibitor's potential as a new oral treatment for various immune-mediated disorders.

VYN202 showed a favorable safety and tolerability profile without any drug-related adverse events in the phase 1a trial as well as "robust pharmacodynamic activity," VYNE said.